ABSTRACT
Objective To observe the efficacy and safety of salvianolate injection combined with pemetrexed and carboplatin in the treatment of elderly patients with advanced non-squamous non-small-cell lung cancer.Methods 58 elderly patients with advanced non-squamous non-small-cell lung cancer in primary treatment were diagnosed by histopathology or cytology confirmation,and they were randomly divided into two groups (29 patients for control group and 29 patients for observation group).The control group was subjected to pemetrexed plus carboplatin chemotherapy,while the observation group was subjected to salvianolate injection based on the treatment of the control group by intravenous drip for 14 days,once a day,200 mg per day,and 21 days was a cycle.The changes of the efficacy,quality of life,the incidence of adverse reactions and the coagulation indicators in the patients of the two groups were compared after 4 cycles.Results The response rates and disease control rates in observation group were 44.8 ％ (13/29),86.2 ％ (25/29) and 37.9 ％ (11/29),75.8 ％ (22/29).It was found that the comparison of efficacy between the two groups did not make any statistical differences (P ＞ 0.05).The improvement of the quality of life in the observation group [82.7 ％ (24/29)] was better than that of the control group [65.5 ％ (19/29)] (P ＜ 0.05).The hematologic toxicity and gastrointestinal reaction rate in the observation group was lower compared with the control group (P ＜ 0.05).Moreover,the improvement of the hypercoagulable states in the observation group was better than that of the control group (P ＜ 0.05).Conclusions The treatment on elderly patients with advanced non-squamous non-small-cell lung cancer by salvianolate injection combined with pemetrexed and carboplatin can reduce the adverse effects caused by chemotherapy,improve the quality of life and the hypercoagulable states.Thereby it might prevent the occurrence of thromboembolic complications.
ABSTRACT
Objective The clinical curative effect observed the empress of the chemotherapy of malignant blood disease big mount of an application IL-2. Methods The review analyzes 65 malignant chemotherapy be over of the blood patient's (treatment set) juniorses to go a big quantity IL-2 treatments,(matched control) choose random of 98 sufferer's chemotherapy be overs don't carry on any immunity treatment behind. Results With visit be over the covariance relapse a rate: the treatment set is 28 %, the matched control is 42 %; Medium exist a period: the treatment set is 44(0～80) months, the matched control is 21(0～80) months. Conclusion For the leukemia, lymphoid lump etc. malignant blood patient the chemotherapy gives after ending big quantity IL-2 immunity treatment is a kind of to cure a method effectively, after maying reduce a sufferer a chemotherapy of relapse a rate, also hope extension existence a period.